MDXG
MiMedx Group, Inc.
MDXG lost money over the past year, so it has no meaningful PE right now. Analysts expect earnings to recover and profitability to improve.
MDXG Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Stable | |
| Strong |
MDXG's balance sheet is currently strong, and its cash flow is stable, but its revenue and profitability are weak.
MDXG PE Valuation
MDXG has no meaningful PE right now: it lost money over the past year.
MDXG Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Decline | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect MDXG's earnings to grow and its profitability to improve, but its revenue to decline.
MDXG Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.07 | — |
| Q3 2026 | -$0.13 | -148% |
| Q2 2026 | $0.04 | -81% |
| Q1 2026 | $0.20 | -26% |
| Q4 2025 | $0.32 | +14% |
| Q3 2025 | $0.27 | -55% |
| Q2 2025 | $0.21 | -66% |
| Q1 2025 | $0.27 | -45% |
| Q4 2024 | $0.28 | -24% |
MDXG has swung to a loss: it lost $0.13 per share over the past year, after a profit the year before.
MDXG Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $62.3M | -45% |
| Q2 2026 | $64.4M | -35% |
| Q1 2026 | $59M | -33% |
| Q4 2025 | $118.1M | +27% |
| Q3 2025 | $113.7M | +35% |
| Q2 2025 | $98.6M | +13% |
| Q1 2025 | $88.2M | +4.1% |
| Q4 2024 | $92.9M | +7% |
MDXG's revenue is shrinking: $62M last quarter, down 45% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -19% | -38 points |
| Q2 2026 | -29% | -41 points |
| Q1 2026 | -27% | -37 points |
| Q4 2025 | 18% | +6 points |
| Q3 2025 | 20% | +6.2 points |
| Q2 2025 | 13% | -14 points |
| Q1 2025 | 9.3% | -6.2 points |
| Q4 2024 | 12% | -19 points |
MDXG's operating margin was −19% last quarter, down 38 points from the same quarter a year ago.
MDXG Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $3.9M | -87% |
| Q2 2026 | -$10M | -169% |
| Q1 2026 | $1.9M | -65% |
| Q4 2025 | $25M | +33% |
| Q3 2025 | $29.3M | +49% |
| Q2 2025 | $14.4M | -34% |
| Q1 2025 | $5.3M | -11% |
| Q4 2024 | $18.8M | +91% |
MDXG generated $21M in free cash flow over the past year, down 69% from the year before.
MDXG Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | -10.1x | Net Cash |
| Q1 2026 | -3.4x | Net Cash |
| Q4 2025 | -2.2x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -2.2x | Net Cash |
| Q1 2025 | -1.5x | Net Cash |
| Q4 2024 | -1.4x | Net Cash |
| Q3 2024 | -0.9x | Net Cash |
MDXG has more cash than debt.
MDXG Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 28.1 | Oversold |
| Stochastic | 15.2 | Oversold |
MDXG's weekly RSI is 28 (oversold) and its Stochastic is 15 (oversold).
MDXG PE vs Healthcare Sector
| Metric | MDXG | Sector median | Relative |
|---|---|---|---|
| PE | 98x | 26x | 278% above |
| PE % | 92 | 29 | 63 pts above |
MDXG has no meaningful PE right now: it lost money over the past year.
MDXG Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $4.09 | 21% below |
| 20 week MA | $4.24 | 24% below |
| 50 week MA | $4.52 | 28% below |
| 100 week MA | $5.92 | 45% below |
| 200 week MA | $6.31 | 49% below |
MDXG is in a downtrend: it's below all five of its weekly moving averages, and 49% below its 200-week average.
MDXG Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $7.25 | $9.40 | +30% |
| 2021 | $9.40 | $6.49 | -31% |
| 2022 | $6.49 | $2.77 | -57% |
| 2023 | $2.77 | $8.77 | +217% |
| 2024 | $8.77 | $9.42 | +7.4% |
| 2025 | $9.42 | $6.90 | -27% |
| 2026 YTD | $6.90 | $3.24 | -53% |
MDXG's yearly returns have swung widely, from +217% in 2023 to −57% in 2022. It's down 53% so far in 2026.